Tivorsan Pharmaceuticals Inc., a biotechnology company pioneering a novel approach to treating Duchenne Muscular Dystrophy and other serious neuromuscular disorders, has appointed James Connolly as chief executive officer and a member of the board. Mr. Connolly is an accomplished business executive with more than 25 years of leadership roles in the pharmaceutical, biotechnology and non-profit sectors. “I’m excited about joining Tivorsan, a company that has the potential to become a significan...